Health Economics›Non-small cell lung cancer›Maintenance after first-line therapy

Maintenance after first-line therapy

Non-small cell lung cancer · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 9 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ipilimumab monotherapy Variant #01	—	R 471 692	84d	~3.8 mo	~14.2 mo	~2	~R 943 384 PFS proxy · indirect	11
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~8.4 mo	~21.9 mo	~19	~R 5 452 150 PFS proxy · indirect	11
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	3.7 mo	—	6	R 343 479 PFS proxy	1
Sunitinib monotherapy Variant #05	—	R 33 433	28d	4.3 mo	—	5	R 167 165 PFS proxy	1
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	3.8 mo	—	3	R 42 639 PFS proxy	1
Erlotinib monotherapy Variant #01	—	R 13 907	28d	2.9 mo	—	4	R 55 628 PFS proxy	2
Gefitinib monotherapy Variant #01	—	R 8 556	28d	4.8 mo	10.9 mo	6	R 51 333 PFS proxy	2
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	5.8 mo	—	7	R 1 702 PFS proxy	1
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	4.3 mo	13.4 mo	7	R 486 PFS proxy	2
Placebo Partial	—	—	—	2.6 mo	11.5 mo	—	—	14
Observation Partial	—	—	—	3.0 mo	—	—	—	1

11 of 11 regimens shown